Intech Investment Management LLC Acquires 44,330 Shares of Xeris Biopharma Holdings, Inc. $XERS

Intech Investment Management LLC grew its holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 88.5% during the second quarter, Holdings Channel.com reports. The firm owned 94,437 shares of the company’s stock after acquiring an additional 44,330 shares during the period. Intech Investment Management LLC’s holdings in Xeris Biopharma were worth $441,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. AQR Capital Management LLC lifted its position in Xeris Biopharma by 13.4% during the 1st quarter. AQR Capital Management LLC now owns 946,766 shares of the company’s stock worth $5,198,000 after buying an additional 111,826 shares in the last quarter. Nuveen LLC bought a new position in shares of Xeris Biopharma in the first quarter worth about $12,240,000. Savvy Advisors Inc. acquired a new position in shares of Xeris Biopharma during the second quarter worth approximately $189,000. Fred Alger Management LLC acquired a new position in shares of Xeris Biopharma during the first quarter worth approximately $736,000. Finally, Vanguard Group Inc. grew its stake in shares of Xeris Biopharma by 2.7% during the first quarter. Vanguard Group Inc. now owns 8,109,644 shares of the company’s stock valued at $44,522,000 after purchasing an additional 210,581 shares during the last quarter. 42.75% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Zacks Research cut shares of Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Xeris Biopharma in a research report on Wednesday, October 8th. Piper Sandler raised their price target on Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a report on Friday, November 7th. Wall Street Zen lowered Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, Oppenheimer restated an “outperform” rating and set a $18.00 target price on shares of Xeris Biopharma in a research report on Friday, November 7th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $9.58.

Insider Activity at Xeris Biopharma

In other Xeris Biopharma news, Director Marla Persky sold 15,500 shares of the company’s stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $7.72, for a total value of $119,660.00. Following the completion of the sale, the director owned 142,000 shares of the company’s stock, valued at approximately $1,096,240. This represents a 9.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Beth Hecht sold 16,667 shares of the stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $7.40, for a total transaction of $123,335.80. Following the completion of the sale, the insider owned 1,336,843 shares in the company, valued at approximately $9,892,638.20. This trade represents a 1.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 55,409 shares of company stock worth $416,381. 6.47% of the stock is currently owned by company insiders.

Xeris Biopharma Trading Up 0.1%

NASDAQ:XERS opened at $7.19 on Friday. Xeris Biopharma Holdings, Inc. has a 1-year low of $3.14 and a 1-year high of $10.08. The firm has a market capitalization of $1.19 billion, a price-to-earnings ratio of -71.84 and a beta of 0.21. The business’s 50-day moving average price is $8.22 and its two-hundred day moving average price is $6.66.

Xeris Biopharma (NASDAQ:XERS) last posted its earnings results on Thursday, November 6th. The company reported $0.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.01). The firm had revenue of $74.38 million during the quarter, compared to the consensus estimate of $74.19 million. Xeris Biopharma has set its FY 2025 guidance at EPS. Sell-side analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current year.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.